Gholamreza Heydari

Gholamreza Heydari

Auto-generated profile, based on publicly available information

Gholamreza Heydari

Tobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2011 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
NGNasim Ghafouri
Nasim Ghafouri
JHJan D Hirsch
Jan D Hirsch
GHGholamreza Heydari
Gholamreza Heydari
Candis M. MorelloCandis M. Morello
Candis M. Morello
GKGrace Kuo
Grace Kuo
RSRenu F Singh
Renu F Singh
In recent years waterpipe smoking has become a popular practice amongst young adults in eastern Mediterranean countries, including Iran. The aim of this study was to assess waterpipe smoking perceptions and practices among first-year health sciences university students in Iran and to identify factors associated with the initiation and maintenance of waterpipe use in this population.

29 July 2012 in Respirology
Verified
Journal Article
Closed access
PDF file
MBMohammad Hossein Boskabady
Mohammad Hossein Boskabady
LFLila Farhang
Lila Farhang
MMMahbobeh Mahmodinia
Mahbobeh Mahmodinia
MBMorteza Boskabady
Morteza Boskabady
GHGholam Reza Heydari
Gholam Reza Heydari

1 February 2012 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
GHG. Heydari
G. Heydari
FTF. Talischi
F. Talischi
STS. F. Tafti
S. F. Tafti
MMM. R. Masjedi
M. R. Masjedi
BACKGROUND: Smoking cessation programmes were first introduced in Iran in 1997. To date a number of types of nicotine replacement therapy have been prescribed. OBJECTIVE: To evaluate the effectiveness of varenicline for tobacco cessation. METHODS: This was a randomised parallel clinical study conducted in 2010. Participants were smokers willing to quit who were visiting a smoking cessation clinic for the first time and were randomly divided into three groups: all three groups received brief counselling on cessation, Group 2 received nicotine patches and Group 3 was prescribed varenicline for 8 weeks. RESULTS: There were 272 participants in the study: 91 in Group 1, 92 in Group 2 and 89 in Group 3. At the end of the first month, 128 of the 272 subjects (47.1%) succeeded in quitting: 17 (18.7%) in Group 1, 60 (65.2%) in Group 2 and 51 (57.3%) in Group 3 (P = 0.000). At follow-up after 12 months, 58 subjects (21.3%) remained smoke-free, of whom 6 (6.6%) were in Group 1, 23 (25%) in Group 2 and 29 (32.6%) in Group 3 (P = 0.000). CONCLUSION: In the study, varenicline treatment was slightly more effective than but not significantly different from nicotine replacement therapy.

5 August 2016 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MAMahshid Aryanpur
Mahshid Aryanpur
MHMostafa Hosseini
Mostafa Hosseini
MMMohammad Reza Masjedi
Mohammad Reza Masjedi
EMEsmaeil Mortaz
Esmaeil Mortaz
PTPayam Tabarsi
Payam Tabarsi
MBMasoud Baikpour
Masoud Baikpour
Tuberculosis (TB) and tobacco use are two major alarming global health issues that tend to be co-prevalent in many developing countries and various surveys have provided evidence on their entangled associations. Accordingly, it is strongly suggested that smoking cessation be incorporated in TB control programs. Therefore, we aimed to evaluate the effectiveness of two smoking cessation methods among newly-diagnosed pulmonary TB patients. A total of 210 newly-diagnosed pulmonary TB patients from Tehran, Iran with smoking habits were included in this randomized clinical trial during 2012–2013. Patients were assigned to three groups of control (just TB medical treatment), brief advice (TB medical treatment plus individualized counseling sessions of quitting behavioral therapy) and combined intervention (TB medical treatment plus individualized counseling sessions of quitting behavioral therapy plus medical treatment with slow release bupropion). Patients’ abstinence was followed at six time point during six months. Data were analyzed by SPSS v.22 using Generalized Estimating Equations (GEE) model. Abstinance rate at the end of six months were 71.7 % for combined intervention group, 33.9 % for brief advice group and 9.8 % for the control group (p < 0.001). Combined intervention group and brief advice group respectively had 35 times (p < 0.001, OR = 35.26, 95 % CI = 13.77–90.32) and 7 times (p < 0.001, OR = 7.14, 95 % CI = 2.72–18.72) more odds of not being an active smoker at each time point, compared to the control group. Considering the prevalence and importance of TB and the substantial influence of these preventive measures on controlling tobacco use, application of such programs is recommended. The survey was registered in the Iranian registry of clinical trials website (irct.ir) in August 31, 2013 with IRCT ID: IRCT2013062613783N1 .

1 January 2014 in Lung India
Verified
Journal Article
Open access
PDF file
MBMohammad Hossein Boskabady
Mohammad Hossein Boskabady
LFLila Farhang
Lila Farhang
MMMahbobeh Mahmoodinia
Mahbobeh Mahmoodinia
MBMorteza Boskabady
Morteza Boskabady
GHGholam Reza Heydari
Gholam Reza Heydari
Background: The prevalence of water pipe (WP) smoking was studied using a standard questionnaire. Pulmonary function tests were also compared between WP smokers and non-smokers. Materials and Methods: The prevalence of WP smoking was studied using a standard questionnaire. Pulmonary function tests including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), maximal mid-expiratory flow (MMEF), peak expiratory flow (PEF), maximal expiratory flow at 75%, 50%, and 25% of the FVC (MEF75,50,25) were compared between WP smokers and non-smokers. Results: A total of 673 individuals including 372 males and 301 females were interviewed. The number of WP smokers was 58 (8.6%) including 24 males (6.5%) and 34 females (11.3%). All pulmonary functional test (PFT) values in WP smokers were lower as compared to the non-smokers (P < 0.05 to P < 0.001). The prevalence and severity of respiratory symptoms (RS) in WP smokers were higher than non-smokers (P < 0.05 to P < 0.001). There were negative correlations between PFT values and positive correlation between RS and duration, rate, as well as total smoking (duration X rate) (P < 0.05 to P < 0.001). Conclusion: In this study the prevalence of WP smoking in Mashhad city was evaluated for the first time. The results also showed a significant effect of WP smoking on PFT values and respiratory symptoms.

1 January 2015
Verified
Journal Article
Open access
GHGholamreza Heydari
Gholamreza Heydari
MHMostafa Hosseini
Mostafa Hosseini
MYMahmoud Yousefifard
Mahmoud Yousefifard
HAHadi Asady
Hadi Asady
MBMasoud Baikpour
Masoud Baikpour
ABAtena Barat
Atena Barat
Smoking and physical inactivity are two major risk factors for non-communicable diseases (NCDs). Not only these factors have a causal effect on NCDs, but they can also affect each other. This study aimed to assess the relationship between these factors as well as their effect on NCDs. A total of 2,602 healthy adults aged 30–60 years participated in this survey in 2010. Data on demographic characteristics, medical history, smoking status, physical activity and anthropometric measures including weight and height were collected and analyzed. The effect of smoking on physical activity was evaluated by logistic regression adjusting for potential confounders. Among demographic characteristics, only age (P<0.001) and educational level (P<0.001) had a significant association with smoking status. Compared with nonsmokers, smokers had an odds ratio of 4.88 (95% CI, 3.34–7.13) for having unsatisfactory physical activity. The present study showed that cigarette smoking negatively affects the quality of physical activity.